Mingyuan Zhang

Mingyuan Zhang

Auto-generated profile, based on publicly available information

Mingyuan Zhang

Department of Hepatology and Gastroenterology, Charité-Universitätsmedizin Berlin, Campus Virchow-Klinikum and Campus Charité Mitte, Berlin, 13353, Germany

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in BioMed Research International
Verified
Journal Article
Open access
PDF file
MZMingyuan Zhang
Mingyuan Zhang
YZYu Zhang
Yu Zhang
LLLili Liu
Lili Liu
MPMozumder Prithweeraj
Mozumder Prithweeraj
HXHongqin Xu
Hongqin Xu
JNJunqi Niu
Junqi Niu
Background and Aims. Alcohol‐associated liver disease is exhibiting an increasing disease burden. In terms of pathogenesis, inflammation is closely related to alcohol‐induced liver injury. The neutrophil‐to‐lymphocyte ratio (NLR) is a novel inflammatory biomarker. Here, we aim to evaluate the role of the NLR and other biomarkers in predicting short‐term mortality in alcoholic cirrhotic patients. Methods. This was a retrospective study that included 459 male alcoholic cirrhosis patients. Among them, 345 patients completed follow‐up. Based on their 30‐day mortality information, patients were separated into surviving and nonsurviving groups. Demographic, clinical, and biochemical features were collected for further analysis. Logistic regression was used to identify factors associated with short‐term mortality, and receiver operating characteristic (ROC) curve analysis was used to establish the predictive value of these factors. Results. The prognostic scores were significantly higher in the nonsurviving group than in the surviving group: NLR: 5.5 vs. 3.2 (P < 0.001), model for end‐stage liver disease (MELD): 15.4 vs. 7.9 (P < 0.001), Maddrey’s discriminant function (MDF): 39.8 vs. 12.7 (P < 0.001), and the integrated MELD (i‐MELD): 37.9 vs. 28.4 (P < 0.001). Logistic regression demonstrated that albumin (ALB), NLR, and i‐MELD values were significantly correlated with patient death in 30 days. On ROC analysis, the diagnostic accuracy for 30‐day mortality of the NLR (area under the ROC curve (AUROC) of 0.72, P < 0.001) was similar to that of the MELD or i‐MELD (AUROCs of 0.71 and 0.74, respectively, P < 0.001). The new biomarker, NLA, calculated as 100 × NLR/ALB, had the best prognostic value. The cutoff values of the NLR and NLA for predicting 30‐day mortality were 4.2 and 19.6, respectively. Conclusions. The NLR and its related biomarker NLA are simple and robust predictors of 30‐day mortality in alcoholic cirrhosis patients.

1 September 2026 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
HLHanyang Liu
Hanyang Liu
MZMingyuan Zhang
Mingyuan Zhang
Frank TackeFrank Tacke
Frank Tacke
Metabolic dysfunction-associated steatohepatitis (MASH) is not solely a disorder of hepatocellular lipid accumulation, but a multicellular disease driven by coordinated metabolic stress, sterile inflammation, fibrogenesis, and niche remodeling. Recent therapeutic progress with the provisional approval of resmetirom and semaglutide has validated MASH as a tractable clinical target. However, many experimental agents have shown limited or inconsistent efficacy, particularly for regression of hepatic fibrosis or cirrhosis, reflecting the biological heterogeneity and dynamic cellular architecture of the disease. Distinct from conventional pathway- or drug class-based reviews, we summarize emerging therapeutics through a liver cell-centered framework, integrating hepatocyte-directed metabolic therapies, immune-cell modulation, hepatic stellate cell-targeted antifibrotic strategies, niche-directed approaches involving liver sinusoidal endothelial cells and cholangiocytes, systemic multi-cell modulators, and precision-delivery technologies. We further compare how these interventions reshape pathogenic communication among hepatic and extrahepatic compartments, while emphasizing unresolved challenges in drug target selection, cellular specificity, disease-stage dependency, safety, and patient stratification. This perspective emphasizes the need to move from isolated pathway targeting toward cell- and network-informed therapeutic strategies supported by spatial multi-omics, human-relevant models, and precision delivery.

12 August 2026 in The Journal of Infectious Diseases
Verified
Journal Article
Closed access
MZMingyuan Zhang
Mingyuan Zhang
XWXiaomei Wang
Xiaomei Wang
HXHongqin Xu
Hongqin Xu
HMHao Meng
Hao Meng
JZJie Zhou
Jie Zhou
JNJunqi Niu
Junqi Niu
Background: Activation of the host immune system is a promising strategy for treating hepatitis B virus (HBV). The stimulator of interferon genes (STING) signaling pathway acts as an innate immune sensor for viral DNA. We aimed to determine whether STING activation can inhibit HBV replication in the liver. Methods: We evaluated STING expression in peripheral blood mononuclear cells and liver biopsy specimens from people with chronic hepatitis B (CHB). We examined the effect of the STING agonist 5,6-dimethylxanthenone-4-acetic acid (DMXAA) on HBV replication and the immune response in a mouse model with persistent HBV replication (rAAV8-HBV1.3). Additionally, we depleted macrophages in vivo to assess their role in DMXAA's antiviral effects. Results: Stimulator of interferon genes expression in people with CHB was higher in the immune-active phase than in the inactive phase or uninfected healthy controls, suggesting an association between elevated STING expression and immune activation. In a mouse model with persistent HBV replication, DMXAA reduced serum HBV DNA in a dose-dependent manner, whereas repeated administration reduced serum HBV DNA, hepatitis B surface antigen, and hepatitis B e antigen levels and enhanced hepatic immune responses. Transcriptome sequencing of liver tissues revealed 856 differentially expressed genes involved in immune-related signaling pathways. In hepatic macrophage-depleted mice, the reductions in HBV virological markers following DMXAA treatment were less pronounced. Conclusions: Stimulator of interferon genes pathway activation enhances the immune response against HBV by upregulating the expression of immune-related genes. Hepatic macrophages play an important role in STING-mediated inhibition of HBV replication.